X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (951) 951
pcsk9 (802) 802
humans (676) 676
cholesterol (524) 524
hypercholesterolemia (444) 444
statins (423) 423
cardiac & cardiovascular systems (396) 396
low density lipoproteins (338) 338
lipids (327) 327
familial hypercholesterolemia (325) 325
pcsk9 inhibitors (310) 310
male (296) 296
proprotein convertase 9 (285) 285
female (249) 249
cholesterol, ldl - blood (246) 246
cardiovascular disease (245) 245
monoclonal-antibody (245) 245
atherosclerosis (238) 238
pharmacology & pharmacy (235) 235
animals (224) 224
density-lipoprotein cholesterol (219) 219
subtilisin/kexin type 9 (212) 212
ldl cholesterol (210) 210
peripheral vascular disease (205) 205
safety (201) 201
efficacy (195) 195
ezetimibe (194) 194
heterozygous familial hypercholesterolemia (191) 191
lipoproteins (191) 191
middle aged (189) 189
alirocumab (181) 181
evolocumab (175) 175
risk factors (172) 172
risk (167) 167
cardiovascular (160) 160
hypercholesterolemia - drug therapy (159) 159
double-blind (157) 157
biochemistry & molecular biology (155) 155
cardiovascular diseases (154) 154
statin therapy (153) 153
monoclonal antibodies (144) 144
proprotein convertase 9 - antagonists & inhibitors (142) 142
ldl-c (141) 141
low density lipoprotein (141) 141
anticholesteremic agents - therapeutic use (139) 139
ldl receptor (138) 138
coronary-heart-disease (137) 137
mice (136) 136
ldl (135) 135
antibodies, monoclonal - therapeutic use (132) 132
ldl-cholesterol (129) 129
aged (128) 128
reducing lipids (126) 126
receptors, ldl - metabolism (125) 125
mutation (122) 122
dyslipidemia (121) 121
cardiology (120) 120
treatment outcome (120) 120
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (118) 118
serine endopeptidases - metabolism (118) 118
clinical trials (117) 117
serine endopeptidases - genetics (117) 117
care and treatment (116) 116
medicine & public health (112) 112
endocrinology & metabolism (111) 111
abridged index medicus (109) 109
statin (109) 109
adult (108) 108
research (108) 108
therapy (108) 108
analysis (107) 107
kexin (107) 107
subtilisin (107) 107
genetic aspects (105) 105
mutations (104) 104
proprotein convertases - antagonists & inhibitors (100) 100
cardiovascular-disease (98) 98
diabetes (97) 97
proprotein convertase subtilisin/kexin type 9 (97) 97
cardiovascular agents (95) 95
atorvastatin (93) 93
health aspects (93) 93
density-lipoprotein receptor (92) 92
proprotein convertases - metabolism (90) 90
disease (88) 88
low-density lipoprotein cholesterol (88) 88
autosomal-dominant hypercholesterolemia (87) 87
medicine, general & internal (87) 87
prevention (87) 87
expression (86) 86
proprotein convertase 9 - metabolism (86) 86
coronary heart disease (85) 85
medical research (85) 85
blood cholesterol (81) 81
hypercholesterolemia - blood (80) 80
low-density-lipoprotein (80) 80
metabolism (80) 80
proprotein convertases (80) 80
internal medicine (79) 79
degradation (77) 77
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1420) 1420
German (19) 19
Spanish (16) 16
Czech (8) 8
French (7) 7
Russian (7) 7
Japanese (3) 3
Korean (3) 3
Italian (2) 2
Slovak (2) 2
Chinese (1) 1
Greek (1) 1
Portuguese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation Research, ISSN 0009-7330, 01/2019, Volume 124, Issue 1, pp. 32 - 37
PCSK9i (protein convertase subtilisin/kexin type 9 inhibitors) are set to revolutionize the treatment of hypercholesterolemia in the management of... 
PCSK9 inhibitors | COST-EFFECTIVENESS | CARDIAC & CARDIOVASCULAR SYSTEMS | drug adherence | PCSK9 | LDL-cholesterol | RECOMMENDATIONS | HIGH-RISK | PERIPHERAL VASCULAR DISEASE | THERAPIES | UPDATE | HEMATOLOGY | lipoprotein(a) | ASSOCIATION | ACCESS | Care and treatment | Hypercholesterolemia | Risk assessment | Analysis | Atherosclerosis | Research | Risk factors
Journal Article
Journal Article
Internal Medicine Journal, ISSN 1444-0903, 08/2017, Volume 47, Issue 8, pp. 856 - 865
Journal Article
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 01/2020, Volume 20, Issue 1, pp. 35 - 47
Introduction: Dyslipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is a key risk factor for atherosclerotic cardiovascular disease... 
PCSK9 inhibitors | alirocumab | cardiovascular outcomes | bococizumab | evolocumab
Journal Article
Medecine des Maladies Metaboliques, ISSN 1957-2557, 03/2019, Volume 13, Issue 2, pp. 147 - 155
Diabetic dyslipidemia, characterized by quantitative, qualitative, and kinetic changes in all major circulating lipids, contributes to the increased... 
PCSK9 monoclonal antibodies | low-density lipoprotein receptor | low-density lipoprotein cholesterol | statins | Diabetes | proprotein convertase subtilisin-kexin 9 (PCSK9) | dyslipidemia
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 09/2017, Volume 140, pp. 8 - 15
Proprotein convertases are serine proteases responsible for the cleavage and subsequent activation of protein substrates, many of them relevant for the... 
Proprotein convertases | Tumor progression | Molecular therapy | CANCER-CELLS | ALPHA-1-ANTITRYPSIN PORTLAND | HEPATOMA-CELLS | OVARIAN-CANCER | FURIN INHIBITORS | POTENT INHIBITORS | PACE4 INHIBITORS | PCSK9 INHIBITION | PHARMACOLOGY & PHARMACY | TUMORICIDAL ACTIVITY | GROWTH-FACTOR | Proprotein Convertases - antagonists & inhibitors | Activation, Metabolic | Drugs, Investigational - pharmacology | Humans | Drugs, Investigational - pharmacokinetics | Drugs, Investigational - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Isoenzymes - chemistry | Prodrugs - chemistry | Molecular Targeted Therapy | Neoplasm Proteins - metabolism | Drugs, Investigational - chemistry | Enzyme Inhibitors - pharmacokinetics | Isoenzymes - metabolism | Enzyme Inhibitors - chemistry | Drug Design | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Binding Sites | Binding, Competitive | Catalytic Domain | Proprotein Convertases - metabolism | Enzyme Inhibitors - pharmacology | Neoplasms - enzymology | Neoplasm Proteins - chemistry | Proprotein Convertases - chemistry | Antineoplastic Agents - chemistry | Enzyme Inhibitors - therapeutic use | Neoplasms - drug therapy | Animals | Prodrugs - pharmacokinetics | Tumor Burden - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Prodrugs - therapeutic use | Neoplasms - pathology | Prodrugs - pharmacology | Isoenzymes - antagonists & inhibitors | Medical research | Proteases | Communicable diseases | Low density lipoproteins | Medicine, Experimental | Development and progression | Amino acids | Ovarian cancer | Index Medicus
Journal Article
Angewandte Chemie International Edition, ISSN 1433-7851, 12/2017, Volume 56, Issue 51, pp. 16218 - 16222
Journal Article
Circulation, ISSN 0009-7322, 12/2017, Volume 136, Issue 23, pp. 2210 - 2219
BACKGROUND:Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are a novel class of medications for patients with familial hypercholesterolemia... 
lipid-lowering therapy | Insurance claim review | PCSK-9 inhibitors | insurance coverage | inhibitors | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | METAANALYSIS | EFFICACY | CHOLESTEROL | SAFETY | AUTOSOMAL-DOMINANT HYPERCHOLESTEROLEMIA | insurance claim review | PCSK-9 | LDL | REDUCING LIPIDS | CARDIOVASCULAR-DISEASE | PERIPHERAL VASCULAR DISEASE | PCSK9 INHIBITORS
Journal Article
Atherosclerosis, ISSN 0021-9150, 03/2018, Volume 270, Issue March, pp. 205 - 210
Journal Article
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, ISSN 0002-7863, 03/2018, Volume 140, Issue 9, pp. 3242 - 3249
The protein-protein interaction between pro protein convertase subtilisin/kexin type 9 (PCSK9) and low-density lipoprotein receptor (LDLR) is a relatively new,... 
NANOPARTICLES | GALACTOSE | LDL-RECEPTOR | CHOLESTEROL | ACCURATE DOCKING | PROTEIN-PROTEIN INTERACTION | DOUBLE-BLIND | C-TERMINAL DOMAIN | BINDING | CHEMISTRY, MULTIDISCIPLINARY | SECRETED PCSK9
Journal Article